In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Philips CEO Finds Comfort In Solid Product Demand As Triple Headwind Blows In

Strategic Approach To Markets Resonates As Customers Look Beyond Sleep Recall

Executive Summary

Frans van Houten has promised a summer update on Royal Philips’ medium-term outlook after the company was hit from all sides in late 2021. He expects the resulting headwinds to persist into early 2022.

You may also be interested in...



Philips At HIMSS22: Informatics Is Taking Pressure Off Providers

Workplace pressures are hitting hospitals and providers still feeling the residual effects of the COVID-19 pandemic. Informatics and connected technologies can take much of the strain, said Royal Philips’ connected care chief Roy Jakobs.

Philips At HIMSS22: Informatics Is Taking Pressure Off Providers

Workplace pressures are hitting hospitals and providers still feeling the residual effects of the COVID-19 pandemic. Informatics and connected technologies can take much of the strain, said Royal Philips’ connected care chief Roy Jakobs.

Philips Trilogy Evo Ventilators, Repair Kits Recalled Because Supplier Used Nonconforming Foam

Specific Trilogy Evo ventilators and their repair kits have been recalled because a Philips supplier incorrectly used polyester-based polyurethane (PE-PUR) foam, a nonconforming material, in the manufacture of their muffler assembly. The US FDA gave the recall a high-risk designation on 26 January.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

IV124999

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel